ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis
Sponsor: First Affiliated Hospital of Guangxi Medical University
Listed as NCT01883180, this PHASE4 trial focuses on Antithymocyte Globulin and Hematopoietic Stem Cell Transplantation and remains completed. Sponsored by First Affiliated Hospital of Guangxi Medical University, it has been updated 9 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2018 — May 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed · Phase: PHASE2 → PHASE4
-
Jun 2017 — Feb 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Guangxi Medical University
- Fujian Medical University Union Hospital
- Guangzhou General Hospital of Guangzhou Military Command
- Nanfang Hospital, Southern Medical University
- Peking University People's Hospital
- Southern Medical University, China
- Xiangya Hospital
For direct contact, visit the study record on ClinicalTrials.gov .